NeuroGyn

NeuroGyn operates at the intersection of medical devices, neuroscience, and pelvic health. Its stated approach combines an implantable device, PosStim, with procedures intended to stimulate pelvic nerve pathways: the patented GNS technique and the laparoscopic LION procedure. This combination distinguishes its described model from a device-only proposition by pairing a neurostimulator with specific implantation and treatment procedures. The intended clinical areas include bladder dysfunction, incontinence, pelvic pain, sexual dysfunction, and other pelvic disorders. The company’s materials emphasize a minimally invasive GNS approach and a design intended for gynecologists, while the LION procedure is described for pelvic surgeons. No specific competitor companies can be named confidently from the available profile, and no similar-company comparisons are provided. Its market position is therefore best characterized by its specialized focus on pelvic nerve applications and its combined device-and-procedure strategy, rather than by a verified ranking against named peers.

NeuroGyn’s known development arc spans its 2014 founding, a recorded CHF 3 million financing round on Dec 26, 2024, and a product portfolio comprising PosStim, the GNS procedure, and the LION procedure. The financing represents an identifiable capital milestone of approximately $3.3 million, but the investor is described only as a business angel, and there is no disclosed valuation or additional round history. The company is listed in the 1–10 employee range, with no specific hiring announcement or reported layoffs. Its products suggest a development strategy focused on translating pelvic neuromodulation into defined implantable-device and surgical-procedure offerings. The clearest potential inflection point in the available history is the 2024 financing, followed by the current articulation of the PosStim System as a combined therapy platform. As a result, growth cannot be reliably assessed through revenue, deployment, or headcount trends; the evidence supports a small, specialized medical-technology company with a documented financing event and a focused product suite.